A major limitation in determining the effects of growth hormone (GH) therapy on overall health has been the duration of studies, which have previously ranged from 1 year to 5 years. Elbornsson et al. now report the outcome of 15 years of GH treatment on body composition and lipid profile in patients with GH deficiency, but some questions remain unanswered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Attanasio, A. F. et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status—3-year results from the HypoCCS Database. J. Clin. Endocrinol. Metab. 87, 1600–1606 (2002).
Elbornsson, M. et al. Fifteen years of growth hormone (GH) replacement improves body composition and cardiovascular risk factors. Eur. J. Endocrinol. http://dx.doi.org/10.1530/EJE-12-1083.
Johannsson, G. et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and hypoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. 82, 727–734 (1997).
Møller, N. & Jørgensen, J. O. Effects of growth hormone on glucose, lipid and protein metabolism in human subjects. Endocr. Rev. 30, 152–177 (2009).
Holmes, S. J., Shalet, S. M. Factors influencing the desire for long-term growth hormone, hormone replacement in adults. Clin. Endocrinol. (Oxf.) 43, 151–157 (1995).
Abs, R. et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults—a KIMS database analysis. Eur. J. Endocrinol. 155, 79–90 (2006).
Sherlock, M. et al. Mortality in patients with pituitary disease. Endocr. Rev. 3, 301–342 (2010).
Ayuk, J. Does pituitary radiotherapy increase the risk of stroke and, if so, what preventative actions should be taken? Clin. Endocrinol. (Oxf.) 76, 328–331 (2012).
Elbornsson, M. et al. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur. J. Endocrinol. 166, 787–795 (2012).
Woodmansee, W. W. et al. Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects. Clin. Endocrinol. (Oxf.) 72, 59–69 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Clemmons, D. Long-term GH therapy—benefits and unanswered questions. Nat Rev Endocrinol 9, 317–318 (2013). https://doi.org/10.1038/nrendo.2013.68
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.68
